Table 2 Extractable nuclear antigen (ENA) antibody typing for siblings II-1 and II-2 at initial presentation, at relapse of disease and 8 months after ofatumumab
ENA antibody typing | Patient II-1 | Patient II-2 | ||||
|---|---|---|---|---|---|---|
At presentation | At relapse | 8 months after ofatumumab | At presentation | At relapse | 8 months after ofatumumab | |
anti-NRNP | negative | negative | positive | negative | negative | equivocal |
anti-SME | negative | negative | positive | negative | negative | positive |
anti-Ro | negative | negative | positive | negative | negative | negative |
anti-La | negative | negative | negative | negative | negative | negative |
anti-Jo-1 | negative | negative | negative | negative | negative | negative |
anti-Scl70 | negative | negative | negative | negative | negative | negative |
other ENA antibodies | weakly positive | negative | negative | weakly positive | negative | negative |